Revance Therapeutics, Inc. - RVNC STOCK NEWS

Revance Therapeutics (RVNC) presented two video abstracts on DAXXIFY™ at the ASDS Annual Meeting, showcasing its efficacy and safety across diverse patient subgroups. Highlights of the presentations include strong patient satisfaction and successful elimination of glabellar lines in black patients, reaffirming DAXXIFY™ as a pioneering treatment in aesthetic medicine. DAXXIFY™ is a FDA-approved long-lasting neuromodulator, promising year-long results with limited treatments. Revance continues to emphasize their commitment to innovation in facial aesthetics.

Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29 in Nantucket, MA. CEO Mark Foley is scheduled to present on September 28 at 9:00 A.M. EST. A live audio webcast will be accessible from the Investor Relations section of the company's website and a replay will be available for 30 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including products like DAXXIFY™ and a biosimilar to BOTOX®.

Revance Therapeutics (NASDAQ: RVNC) announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal regarding the effects of DAXXIFY™ on glabellar lines. The studies showed DAXXIFY™ significantly improved eyebrow position with a response duration of over 24 weeks across various age and race subgroups. In a post-hoc analysis, patients experienced a positive reduction in frontalis muscle activity. The safety profile was consistent across demographics, with common adverse events including headache and injection site reactions.

Revance Therapeutics presented positive results from its Phase 2 JUNIPER clinical trial for DAXXIFY™, targeting upper limb spasticity in adults post-stroke or brain injury. The 500U dose showed a median response duration of 24 weeks and was well tolerated. The drug's effectiveness may potentially reduce treatment frequency by 50% annually. Results will be shared at the MDS Congress on September 16, enhancing the company's prospects in a market valued at $756 million, projected to exceed $1 billion by 2025.

Revance Therapeutics announced the closing of its public offering of 9.2 million shares at $25.00 per share, raising gross proceeds of $230 million. The offering saw the complete exercise of the underwriters' option for 1.2 million additional shares. The shares were offered under an automatic shelf registration statement previously filed with the SEC on November 27, 2020. Goldman Sachs, Cowen, Guggenheim, and Barclays acted as joint book-running managers for this offering, with full details available on the SEC's website.

Revance Therapeutics has priced an upsized public offering of 8,000,000 shares of common stock at $25.00 per share, aiming to raise approximately $200 million in gross proceeds. The offering is expected to close around September 15, 2022, subject to customary conditions. Proceeds will fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers, and OPUL®, alongside general business operations, research, and development. The underwriters have a 30-day option to purchase an additional 1,200,000 shares at the same price.

Revance Therapeutics (RVNC) announced a proposed underwritten public offering of $150 million of its common stock, with a potential for an additional 15% from underwriters. The proceeds will fund commercialization of DAXXIFY™, the RHA® Collection, and OPUL®, alongside general corporate purposes. The offering is subject to market conditions and completion is not guaranteed. Goldman Sachs, Cowen, Guggenheim Securities, and Barclays are managing the offering. The offering is being made under an automatic shelf registration statement.

Revance Therapeutics, Inc. (RVNC) has received FDA approval for DAXXIFY™ (daxibotulinumtoxinA-lanm), the first long-acting neuromodulator for treating moderate to severe frown lines in adults. This product showcases a median efficacy duration of six months, with some patients experiencing results lasting up to nine months. DAXXIFY™ is formulated with Peptide Exchange Technology™ and does not contain animal-derived components. The approval strengthens Revance's position in the $3.2 billion U.S. facial injectables market and indicates potential for future therapeutic applications.

Revance Therapeutics (Nasdaq: RVNC) reported a strong second quarter 2022, achieving total revenue of $28.4 million, up 51% from $18.8 million in Q2 2021. The RHA® Collection contributed $25.5 million to this total. Selling, general, and administrative expenses decreased to $47.8 million due to cost management. Additionally, R&D expenses fell to $24.9 million.

The company anticipates a PDUFA date of September 8, 2022, for DaxibotulinumtoxinA, with hopes for future growth fueled by the recent launch of RHA® Redensity.